BiotechProfSchleuning invests in biotech companies in the USA with a focus on new immunotherapies/oncology. The companies have a market capitalization that is roughly between $50 million and $900 million. We focus on companies that have one or more drugs/preparations/applications in Phase 3 clinical trials. For our companies, we strive to have direct, personal contact with (a) scientific leadership and (b) CEOs.
We participate in companies that convince us mainly by their scientific approach and a top-class scientific team. Thus, one or the other Nobel Prize winner can be found in the companies. The companies should achieve significant development steps – from the time of the investment – within 9 to 20 months. The companies are traded on the markets of NYSE, AMEX, NASDAQ or via OTC exchanges. We aim – in addition to these trading venues – for direct company investments.